A phase II, open label study of biomarkers to assess response in patients with metastatic castration-resistant prostate cancer treated with radium-223.
Disease site: Prostate cancer
Treatment modality: Radiopharmaceutical, systemic therapy
Status: In follow-up
REASURE is a phase II, multicentre, randomised trial of radium-223 incorporating diffusion-weighted MRI (DW-MRI) and PET imaging with collection of blood, urine and bone marrow samples. REASURE aims to identify potential markers of response to treatment with radium-223 in patients with castration-resistant prostate cancer with bone metastases.
38 patients will be recruited from four UK sites over 18 months. Patients will be randomised to receive a monthly radium-223 injection at a dose of either 50 kBq/kg or 80 kBq/kg for up to 6 months. Patients will be followed up every 4 months for 1 year after their last treatment of radium-223.
Chief Investigator: Dr Chris Parker, The Royal Marsden NHS Foundation Trust
ICR-CTSU Scientific Lead: Dr Emma Hall
Trial management contact: [email protected]
Sponsor: The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust
Funding: Bayer HealthCare Pharmaceuticals Inc.
Further information including recruitment progress is available from the UKCRN portfolio.
The plain English summary is available from Cancer Research UK.
Publications and presentations
There have been no presentations or publications to date.